LifeStance Health reports new anxiety medications are expected for 2026, featuring innovative treatments in clinical trials ...

Please provide your email address to receive an email when new articles are posted on . Treatment of generalized anxiety disorder with an antidepressant increased the treatment response rate by 41%.

Mind Medicine (MindMed) Inc. achieved positive results from phase 2b MMED008 study using MM-120 for the treatment of patients with generalized anxiety disorder. End-of-phase 2 meeting with the FDA for ...

Cybin Inc. (the "Company") doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) ("Helus Pharma"), a clinical stage ...

Anxiety disorders are among the most prevalent mental health conditions globally, affecting millions of individuals across various age groups. Characterized by persistent and excessive worry, fear, or ...

The Food and Drug Administration has granted the company’s LSD treatment for generalized anxiety disorder a “breakthrough therapy” status. A single oral administration of 100 micrograms MM120 in ...

The device is designed to transcutaneously deliver low-level electrical stimulation to the skin behind the ears. The Food and Drug Administration (FDA) has cleared Modius Stress, a transdermal, ...

In a world of constant connectivity and mounting pressures, generalized anxiety disorder (GAD) has emerged as a significant mental health challenge affecting millions. Recent studies show that anxiety ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. PsiGAD psilocybin-assisted therapy demonstrated a ...